Multiplexed CRISPR technologies, in which numerous gRNAs or Cas enzymes are expressed at once, have facilitated powerful biological engineering applications, vastly enhancing the scope and efficiencies of genetic editing and transcriptional regulation. In this review, we discuss multiplexed CRISPR technologies and describe methods for the assembly, expression and processing of synthetic guide RNA arrays in vivo. Applications that benefit from multiplexed CRISPR technologies, including cellular recorders, genetic circuits, biosensors, combinatorial genetic perturbations, large-scale genome engineering and the rewiring of metabolic pathways, are highlighted. We also offer a glimpse of emerging challenges and emphasize experimental considerations for future studies.
Most archaea and about half of bacteria carry the genes necessary for CRISPR–Cas adaptive immunity, which provides a memory of prior infections by encoding short DNA sequences into CRISPR (clustered regularly interspaced short palindromic repeats) loci within their genome. These prior infections are stored as spacer sequences, each of which is flanked by repeat sequences. Spacer repeats are transcribed into pre-crRNA (CRISPR RNAs), which are then processed into functional crRNAs1. Native CRISPR–Cas systems are inherently multiplexed; organisms can encode one or several CRISPR arrays and express numerous Cas (CRISPR-associated) proteins that facilitate the acquisition of new spacers and process the CRISPR arrays2.
Over the last few years, thousands of studies have employed CRISPR–Cas technologies to edit, or transcriptionally regulate, individual genetic loci based on their sequence complementarity with designed guide RNAs (gRNAs). Despite the general utility of CRISPR–Cas technologies, the use of an individual gRNA limits efficiencies and biotechnological applications. Therefore, there is now a growing trend in studies that move away from mono-guide approaches, and instead use multiplexed strategies for multi-locus editing or transcriptional regulation. While only four PubMed papers mentioned “multiplex” and “CRISPR” in 2013, 81 such papers were published in 2018. CRISPR systems underpinning bacterial adaptive immunity function thanks to an intricate dance between CRISPR arrays and multiple Cas enzymes; the core of this review advocates for a return to this “natural state” and emphasizes the advantages of expressing multiple Cas proteins or gRNAs simultaneously in vivo to edit or transcriptionally regulate numerous genetic loci in parallel.
In this review, we highlight strategies to create and process synthetic gRNA arrays in a multitude of organisms, emphasize the utility of inducible and orthogonal CRISPR–Cas technologies, and discuss the plethora of applications made possible by parallel targeting of genes in vivo, including biosensing, large-scale genome engineering, the construction of logic circuits, and metabolic engineering. We also argue for an enhanced focus on rigorous, quantitative experiments to fully validate and study gRNA functions in vivo, and describe the suite of computational tools available to design gRNAs. Finally, we conclude with outstanding challenges and future scientific directions ripe for innovation in the CRISPR multiplexing field.
CRISPR for gene editing and transcriptional regulation
While many Cas proteins have been discovered, Cas9 and Cas12a (also known as Cpf1), which are RNA-guided endonucleases that cleave target DNA, are the most commonly used for genetic editing and transcriptional regulation3. Cas9 and Cas12a are remarkably simple to program and can be directed to DNA targets via Watson-Crick base pairing between the genetic target and gRNA. In native CRISPR systems, gRNAs for Cas9 are comprised of a crRNA:tracrRNA complex, which can be fused together via genetic engineering to form a sgRNA (single gRNA), while those for Cas12a consist solely of a crRNA3,4. To avoid confusion throughout this review, we use the term ‘gRNA’ to represent all CRISPR gRNA formats4. After forming a ribonucleoprotein complex with a gRNA, Cas9 and Cas12a perform a double-strand break adjacent to a protospacer adjacent motif (PAM), a sequence that is required for target recognition and varies between endonucleases4. This double-strand break enables genome editing applications.
By mutating specific amino acids in Cas9 and Cas12a, DNA cleavage activity in these enzymes is abolished, thus converting them into nuclease-null mutants, denoted as dCas9 and dCas12a5. Fusion of dCas enzymes to effector domains enables efficient transcriptional regulation, including CRISPR-mediated inhibition (CRISPRi) and activation (CRISPRa)5,6. Mechanistically, dCas enzymes repress transcription by preventing the binding of RNA polymerase or, if targeted to open reading frames, by interfering with transcription elongation5,7. In eukaryotes, dCas is typically fused to an effector domain to enhance repression by recruiting chromatin remodeling proteins while, in bacteria, dCas enzymes alone are usually sufficient to repress gene expression by physically blocking RNA polymerase5,6,8. Similarly, effector domains for CRISPRa work by recruiting RNA polymerase or by recruiting endogenous transcriptional activators6,7,9,10,11,12,13.
Both CRISPR-based gene editing and transcriptional regulation benefit from multiplexing (Fig. 1). By producing multiple gRNAs and a Cas protein in vivo, researchers can build layered genetic circuits that control cellular behavior or modulate metabolic pathways with the simultaneous editing, activation, and downregulation of multiple target genes14,15,16,17. For gene editing, CRISPRa and CRISPRi, the targeting of multiple gRNAs to a single genetic locus also enhances the efficiency of DNA editing and transcriptional control18,19,20.
Importantly, many methods to express and process multiplexed gRNAs in vivo are based on crRNA-processing mechanisms found in native CRISPR systems. To process CRISPR arrays, some native systems rely on the nuclease itself (e.g., Cas12a and Cas13a), some rely on accessory proteins that are part of the final effector complex (e.g., Cas6/Csy4 as part of Cascade), and others rely upon a combination of tracrRNA (transactivating crRNA) and RNase III (e.g., Cas9, Cas12b, and Cas12c)21.
Transcription and processing of gRNA arrays
While a simple approach to target multiple genetic loci at once in vivo is to simply transfect cells with preformed ribonucleoprotein complexes, many applications (discussed in the following sections) demand sustained functionality of CRISPR–Cas over time. Fortunately, in recent years, many strategies to genetically encode, transcribe and process large numbers of gRNAs in vivo have been developed.
There are three main “genetic architectures” for multiplexed gRNA expression. In both eukaryotes and bacteria, multiple gRNAs can be expressed by encoding each under the control of an individual promoter (typically Pol III U6 promoters in mammalian cells and Pol III tRNA promoters in yeast and plants) and terminator (Fig. 2a). Pol III promoters are high fidelity, but have a lower processivity than Pol II promoters22. Both Pol II and Pol III promoters have been used to express gRNAs for CRISPR–Cas studies, but Pol II promoters are easily tuned and often inducible.
In the second type of genetic architecture for multiplexed gRNA expression, gRNAs are encoded and processed by mechanisms derived from native CRISPR–Cas systems. For example, arrays of gRNAs can be processed by RNase III in a tracrRNA-dependent manner, which is the same mechanism by which crRNAs are processed in Type II CRISPR systems (Fig. 2b)21. This strategy enabled at least four genetic loci to be edited simultaneously in Saccharomyces cerevisiae, Escherichia coli, and cell-free extract23. The intrinsic crRNA-processing capabilities of Cas12a have also been leveraged to process a large number of gRNAs from a single RNA transcript, both constitutively and inducibly (Fig. 2c)23,24,25. Cas12a cleaves pre-crRNA via recognition of hairpin structures formed within the spacer repeats, producing mature crRNAs26. Tandem expression of Cas12a and an array of crRNAs from a single Pol II promoter in human cells enabled five target genes to be cleaved, and an additional ten target genes to be transcriptionally regulated, concurrently24. Multiplexed targeting via Cas12a has also been demonstrated in plants, yeast, and bacteria27,28,29. In addition, spacers for both Cas9 and Cas12a can be transcribed and processed from a single array simultaneously, with the spacers for Cas9 processed by endogenous tracrRNA-dependent RNase III23.
A third architecture for multiplexed gRNA expression is to produce a single transcript encoding multiple gRNAs, each separated by RNA cleavage sequences. This enhances the modularity and stoichiometry of gRNAs in vivo for CRISPR multiplexing, but demands that additional processing mechanisms are implemented to produce functional gRNAs from a single array24. Common strategies to accomplish this include co-expression of RNA processing enzymes, such as Csy4, or by flanking each gRNA with self-cleaving ribozymes or tRNAs.
Multiplexing can be achieved from long RNA transcripts by flanking each gRNA with the virus-derived, cis-acting Hammerhead and hepatitis delta virus ribozymes. This strategy is amenable to both Pol II and Pol III-mediated transcription and has been demonstrated in multiple organisms (Fig. 2d)30,31,32.
gRNA arrays can also be expressed from Pol II or Pol III promoters and excised by Cas family endonucleases, such as Csy4, which processes pre-crRNAs in some native CRISPR systems (Fig. 2e)33. Csy4 recognizes a 28-nt stem–loop sequence in RNA transcripts and cleaves after the 20th nucleotide33. By flanking each gRNA in an array with the Csy4 recognition sequence, multiple gRNAs can be expressed and processed from a single promoter in mammalian cells, yeast, and bacteria30,34,35. Our group previously expressed and processed 12 sgRNAs in S. cerevisiae from a single Pol II promoter with co-expression of Csy420. Though Csy4-mediated processing of gRNA arrays enables a large number of gRNAs to be processed from a single RNA transcript, co-expression of Csy4 is sometimes undesirable because of cytotoxicity at high concentrations30.
Numerous studies have also exploited endogenous tRNA-processing machinery to process arrays of gRNAs flanked by 77-nt long pre-tRNA genes36,37,38. Processing of pre-tRNAs is mediated by ribonucleases P and Z, which cleave near the 5′ and 3′ ends, respectively, of each pre-tRNA (Fig. 2f). RNase P and Z are found in all domains of life and thus enable numerous gRNAs to be processed from tRNA–gRNA arrays in many organisms. tRNA–gRNA arrays can also be encoded in eukaryotic introns and processed by the spliceosome complex, an approach that enabled both an endonuclease (encoded in an exon) and multiple gRNAs to be expressed from a single Pol II promoter in rice protoplasts39.
Remarkable progress has been made in harnessing biomolecular mechanisms to produce and process increasingly long gRNA arrays. However, it is still often technically challenging to create these synthetic arrays due, in part, to the presence of highly repetitive DNA sequences.
Methods for assembly of highly repetitive gRNA arrays
Most methods to assemble gRNA arrays do so via derivatives of popular cloning methods, such as Gibson or Golden Gate Assembly, since the repetitive sequences within gRNA arrays often make pure chemical synthesis unviable40,41. Assembly approaches for building synthetic gRNA arrays can be further divided into those purpose built for a specific organism, and more general strategies.
Many systems to build synthetic arrays utilize plasmid-based cloning toolkits in which annealed oligonucleotides encoding gRNAs are ligated into digested plasmids with predesigned Type IIs restriction sites. Golden Gate, Gibson Assembly, or recombination is then used to join multiple gRNA-expressing entry vectors together into a digested vector, which contains a promoter and terminator for expression of the assembled array (Fig. 3a). Conversely, some methods use annealed oligos containing complementary overhangs that specify the order of each gRNA “unit”, thus enabling their direct ligation into a digested vector23. Array assembly methods of this type are rapid and easy to use, and have been reported for many organisms34,38,42,43,44,45.
Other options to produce gRNA arrays rely on a smaller set of plasmid-based parts to produce gRNAs and clone them into arrays (Fig. 3b). In these "lightweight" systems, one plasmid is typically used as a template to produce PCR amplicons, each of which is a gRNA “unit” consisting of 5′ and 3′ Type IIs restriction sites, a full gRNA, and a direct repeat, Csy4 recognition site, ribozyme, or other repetitive sequence. Units are digested and ligated into a destination vector, thus completing a functional array for in vivo gene expression20,46. We previously used this approach to build an array with 12 gRNAs, each flanked by Csy4 recognition sites, using two plasmids in just two days20. A slight variation of the same strategy also enabled the assembly of an array with 24 gRNAs, each flanked by a Csy4 recognition site47.
gRNA arrays flanked by direct repeats can also be constructed by ligating together synthesized DNA fragments, each containing 2–6 gRNAs (Fig. 3c). This general strategy of “synthesis and ligation” enabled the assembly of a single transcript that encodes 25 gRNAs for multiplexing in mammalian cells23,24. Recent efforts have also sought to reduce the number of repetitive sequences within gRNAs themselves, thus enabling the synthesis of DNA fragments encoding extra long gRNA arrays48. The handle of Cas9 sgRNAs (the portion that binds Cas9) is 42-nt in length and makes direct synthesis challenging. To circumvent this limitation, a recent study designed and validated a library of orthogonal, nonrepetitive Cas9 handles, promoters and terminators for E. coli, thus enabling up to 22 sgRNAs—each expressed from an individual promoter and terminator—to be synthesized in 3 kb chunks and ligated together48.
As synthetic gRNA arrays grow in length, however, it is important to consider the strategies employed to process the RNA transcripts. With long arrays, Pol III-based methods, including tRNA-mediated processing, quickly become unfeasible due to limitations on processivity (only up to eight gRNAs have been produced from this type of array)38. The best strategies to achieve higher multiplexing of gRNAs thus far seem to rely either on co-expression of Csy4 or on the self-processing and targeting capabilities of Cas12a20,24. Both of these strategies are used by native systems to produce and cleave CRISPR arrays, lending credence to their ability to efficiently process very long, repetitive RNA transcripts3,33,49.
Efficiencies of multiplexed gene editing, CRISPRi, and CRISPRa
Cas enzymes can either be programmed to target many genes at once, or multiple gRNAs can be directed to a single genetic locus to enhance the efficiency of editing or transcriptional regulation (Table 1). A recent study in mammalian cells, for instance, demonstrated that the efficiency of Cas12a-mediated editing with 10 gRNAs directed to a single locus is about 60%, whereas individual gRNAs had much lower efficiencies (ranging from 2 to 17%)24.
In most cases, however, it is desirable to direct gRNAs to multiple genetic loci at once. Targeting of Cas9 to ten different genes in human cells simultaneously has demonstrated that gRNAs expressed from arrays mediate genetic disruptions at efficiencies similar to gRNAs tested at each locus individually34. In rice protoplasts, four chromosomal deletions (eight total loci) have been performed simultaneously with 4–45% efficiency36. In S. cerevisiae, gRNA arrays have been used to implement up to eight simultaneous gene disruptions at once, with 86.7% of cells having all eight disruptions38. At least four genes have also been disrupted concurrently in E. coli with efficiencies greater than 30%50.
Multiplexed gRNAs are not only beneficial for gene editing, though. gRNA arrays are increasingly being utilized to tune the transcription of multiple genetic loci in tandem. In human cells, for example, ten genes have been transcriptionally repressed at once with dCas12a-based CRISPRi, with efficiencies ranging from 40 to 80%24. Our lab has previously expressed up to 12 sgRNAs from a single promoter in S. cerevisiae, targeting 4 sgRNAs to three distinct genes in parallel, with transcriptional repression efficiencies between 81 and 95%20. In E. coli, four loci have also been repressed simultaneously by dCas12a by about 50-fold each51.
CRISPRa applications also benefit from multiplexing. In human cells, dCas12a-based activators with three gRNAs targeting a single gene increased gene activation by 9- to 40-fold relative to single gRNAs while, with dCas9-VPR (a tripartite activator comprised of VP64–p65–Rta), four sgRNAs targeting a single gene enhanced gene activation by more than 1000-fold11,18,19,52. Three to sevenfold activation of three genes in rice protoplasts has also been achieved, but required a modified dCas9-fusion protein53.
To ensure efficient editing or transcriptional regulation by multiplexed gRNAs, predictive algorithms and computational tools to design optimal gRNAs will prove crucial. Considerable progress has been made in designing computational tools and incorporating biological factors into de novo predictions of gRNA efficiencies, but further developments are required (Box 1).
Orthogonal and inducible CRISPR–Cas technologies
As the number of gRNAs in a biological system increases, researchers must implement control mechanisms to limit cross talk between components and minimize off-target effects. Additional control over CRISPR–Cas can be implemented by expressing multiple Cas orthologs in vivo, by creating inducible systems wherein CRISPR–Cas components are expressed only when they are needed, or via direct engineering of gRNAs (which has been reviewed elsewhere)54.
Cas orthologs from different organisms each recognize a slightly different gRNA structure, enabling orthogonal assembly of ribonucleoprotein complexes. For Cas9, the nexus and hairpin of an sgRNA dictates which Cas9 ortholog they associate with (e.g., SpCas9 from S. pyogenes vs. SaCas9 from S. aureus), and swapping the nexus and hairpin regions alters which Cas ortholog is recognized55. Promiscuous fusion gRNAs (fgRNAs), which can associate with either Cas9 or Cas12a, have also been developed56. In yeast, Cas enzymes for gene editing, CRISPRa and CRISPRi have been expressed simultaneously in vivo, and functioned orthogonally simply by expressing three different gRNA architectures15.
Other strategies to minimize cross talk have utilized truncated gRNAs which, in some cases, are unable to mediate cleavage of target DNA, but can still recognize a genetic locus and mediate transcriptional regulation7. Normal length gRNAs, on the other hand, preferentially mediate cleavage of target DNA. By encoding both short and long gRNAs from a single array, and co-expressing both active and nuclease-null versions of Cas12a in human cells, simultaneous gene editing and transcriptional regulation of 15 genes was achieved in tandem24.
Expression of dCas9 is toxic in bacteria, and expression of additional dCas9 enzymes could further burden cells8,57. To overcome this in E. coli, scaffold RNAs (scRNAs), which are modified sgRNAs that encode both a target sequence and an RNA hairpin that recruits specific effector proteins, were used for bifunctional CRISPRi/CRISPRa with a single dCas enzyme9. This strategy, in which orthogonal scRNAs are used in lieu of expressing multiple different endonucleases, is also applicable in yeast and human cells58. T7 polymerase, a single-subunit enzyme that recognizes a short, 17 bp promoter, has also been used for orthogonal expression of sgRNAs in different yeasts, including S. cerevisiae and Yarrowia lipolytica59.
Cas enzymes can also be turned “on” selectively, either to limit toxicity or to enhance programmability, by linking endonuclease expression to light- or chemical-inducible promoters9,60. In the near future, we suspect that strategies leveraging anti-CRISPR proteins to rapidly turn “off” endonuclease functions will also be deployed61. Other strategies to control CRISPR–Cas activity rely on modifications to the structure of sgRNAs; conditional gRNAs are either constitutively active and turned “off” by RNA terminator switches, or are constitutively inactive and turned “on” by an RNA trigger62. This strategy has been demonstrated in both bacteria and human cells, enabling programmable CRISPR–Cas activity in vivo.
sgRNA behaviors can also be controlled by appending inducible, spacer-blocking hairpins to sgRNAs, which abrogates their ability to transcriptionally regulate target genes until they are turned “on” by a genetically encoded or exogenous signal63. Another method for inducible activation is to flank each sgRNA with microRNA-complementary binding sites64. In the presence of cognate microRNAs or short interfering RNAs (siRNA), functional sgRNAs are produced via Argonaute2 (Ago2)-mediated cleavage, an enzyme that cleaves mRNAs with sequences complementary to a microRNA or siRNA65. Recently, “switchable” Cas12a gRNAs with 5′ extensions have also been reported in bacterial cells, which are activated in response to a single-stranded RNA trigger, including full length mRNAs66.
With strategies to minimize cross talk between orthogonal Cas enzymes and gRNAs facilitating the implementation of multiplexed CRISPR applications, a range of biological and engineering applications have become accessible.
Applications enhanced by multiplexed CRISPR technologies
Multiplexed CRISPR–Cas technologies have advanced numerous applications in basic science, synthetic biology, and biotechnology. Though there are too many applications to discuss here, we highlight those topics which specifically benefit from multiplexed strategies, such as combinatorial mapping of genotype-to-phenotype, rapid strain and metabolic engineering, multi-input biosensing, multi-event recording in living cells, and multi-layered, digital logic circuits (Fig. 4).
CRISPR-based genetic circuits
One of the main objectives of synthetic biology is to construct genetic circuits that can control cellular behavior, but there have been serious challenges to this endeavor. A lack of well-characterized, orthogonal parts means that it is difficult to scale circuits and connect many individual regulators together8. The programmability of RNA:DNA base pairing, enabled by CRISPR–Cas systems, has facilitated the construction of large logic circuits with many orthogonal regulators. In yeast, 20 gRNA–promoter pairs have been shown to operate orthogonally and, in bacteria, at least 5 pairs have been demonstrated14,16.
Numerous studies have implemented multiplexed, CRISPR-based logic in human, yeast, and bacterial cells (Fig. 4a)14,16,67. For example, a central processing unit consisting of dCas9 fused to a transcriptional repressor has been used, together with multiple sgRNAs, to construct layered NOR gates in E. coli and numerous bitwise operators in human cells14,67. A NOR gate is a type of Boolean operator that produces an output signal only if both inputs are negative. A CRISPR-based NOR gate, therefore, constitutively produces an output signal (e.g., GFP or a gRNA), but is turned off when a gRNA binds to its promoter and represses transcription. In yeast, dCas9-based NOR gates with up to seven layers have been constructed16. In E. coli, NOT and NOR gates with up to five sgRNAs have also been coupled to native regulatory networks, where the output of a logic circuit is used to control a cellular phenotype, such as sugar utilization or chemotaxis14.
Such logic circuits have also been used to detect specific cell types and produce therapeutic payloads in response. In bladder cancer cells, for example, simultaneous activation of two cell type-specific promoters were linked to the output of different effector genes that could trigger cell death, arrest growth, or impair cell motility68. CRISPR-based logic circuits offer a programmable means to detect different biomarkers as inputs—which makes them a foundational tool for the assembly of more complex biosensors—and can actuate therapeutic payloads in response to such inputs67.
Multi-input biosensing and diagnostics
Cas enzymes can be programmed to detect and cleave specified RNA or DNA sequences, making them a logical choice for biosensor development (Fig. 4b)69. Multiplexed strategies are again advantageous because the addition of gRNAs enables numerous pathogens to be detected in a single assay or multiple markers to be analyzed for a single pathogen, thus reducing costs, improving accuracy, and broadening diagnostic utility.
In vitro biosensors for viral and bacterial pathogens often rely on Cas13a (previously known as C2c2), which is a programmable RNA-guided RNase, and Cas12a70. Importantly, there are many orthologs of Cas12a and Cas13a71. Following DNA or RNA amplification72,73, Cas13a and Cas12a in complex with a gRNA recognize a target RNA or DNA, respectively. Upon target recognition, both enzymes nonspecifically cleave nearby RNAs or ssDNAs, respectively, in a process known as collateral cleavage74. By adding single-stranded RNA or DNA fused to fluorescent probes, this collateral cleavage mechanism can be exploited to conditionally produce a visible output only after formation of Cas12a/Cas13a complex hybridization with the target sequence and cleavage of the fluorescent probes, thus releasing the output signal72,73. By expressing multiple Cas13a and Cas12 orthologs and tuning the single-stranded linkers in these fluorescent probes, multiple reporter outputs can function orthogonally, increasing the number of pathogens that can be detected in a single assay73.
In vitro DNA-based biosensors have also enabled detection of pathogens, like Mycobacterium tuberculosis, by fusing two separate dCas9 enzymes to split halves of an output signal, such as luciferase. Each dCas9-fusion protein is programmed by sgRNAs that recognize proximal positions on an M. tuberculosis target sequence. Luminescence is generated when each dCas9 split-pair recognizes, and binds, to the DNA target, thus bringing the luciferase halves together75.
Combinatorial mapping of genotype to phenotype
For decades, researchers have deleted genes and studied their phenotypic impact in a range of organisms, shaping our understanding of how the genome encodes information and regulates behavior. Unfortunately, rapid methods to delineate how combinations of genes contribute to a phenotype have been sorely limiting. CRISPR multiplexing can be used to probe these combinatorial, genotype-to-phenotype questions by perturbing combinations of genes in tandem, wherein sequence-based readouts of a genetic barcode (each mapped to a specific sgRNA sequence) is used to determine which cells received which sgRNAs (Fig. 4c).
To systematically dissect gene interactions responsible for ovarian cancer cell growth, one study used a library of 23,409 barcoded, gRNA pairs targeting fifty different genes encoding epigenetic regulators, based on known ovarian cancer drug targets76. Each gRNA was produced from an individual promoter, and lentiviral transduction of each gRNA pair, followed by serial passaging of the ovarian cancer cells and sequencing of barcode frequencies over time, elucidated pairs of gRNAs that inhibit cancer growth.
Similar combinatorial gRNA libraries have also been used with CRISPRi to explore how combinations of enhancers regulate the expression of estradiol-responsive genes and to map enhancer-gene pairs in human cells77,78. In the latter example, approximately 28 CRISPRi perturbations were made per cell using lentiviral transductions, and transcriptional repression of genetic loci was read out by single-cell RNA sequencing. By transducing random, triple combinations of sgRNAs, each expressed from an individual promoter, combinatorial perturbations by gRNAs were also used to determine genes involved in the unfolded protein response (a cellular stress response pathway) in human cells by screening for cells with perturbed homeostasis of the endoplasmic reticulum79.
Multiplexed cellular recording
CRISPR-based bacterial adaptive immunity is a molecular recorder, whereby cells record past infections as spacers in the genome. CRISPR technologies have enabled the construction of DNA-based cellular recording devices that can provide temporal and spatial information for a milieu of biological questions (Fig. 4d)80.
In practice, CRISPR-based DNA memory devices require three elements: sensing of a signal, the writing of that signal into DNA, and the readout of the modified DNA (typically via sequencing of the loci) to reconstruct the information80. The first element, sensing, relies on protein sensors that transduce signals into the expression of a gRNA, which then serves as the ‘writing’ element to record the presence of that signal at a specified locus.
Multiplexed gRNAs can be used to record multiple input signals, including their duration, strength, and the order in which they appear81. CAMERA (CRISPR-mediated analog multi-event recording apparatus), for example, can simultaneously sense and record exposure to two antibiotic signals in tandem by using a base editor to convert C•G → T•A at specified loci. Further sgRNA multiplexing may enable the sensing and recording of additional signals. Other multiplexed recorders have also been developed, which can be ‘layered’ and interconnected, like genetic circuits, to both record and control molecular events in both bacterial and eukaryotic cells82.
Genome, strain, and metabolic engineering
Multiplexed CRISPR–Cas technologies have been applied, with incredible success, for both rapid genome editing and for the transcriptional rewiring of metabolic pathways (Fig. 4e). CRISPR multiplexing has enabled genome editing strategies that would be difficult, or impossible, to achieve with traditional genetic engineering methods. Programmable, large-scale genome rearrangement and assembly in E. coli was recently performed by expressing six gRNAs; two that cut the genome and four others that cut a bacterial artificial chromosome (BAC), enabling large (greater than 100 kb) genome fragments to be rearranged at will83. A similar CRISPR multiplexing strategy was also used to build a chemically synthesized, 61-codon E. coli genome, where DNA megachunks were placed onto BACs and incorporated into the genome via multiplexed cleavage of dsDNA and lambda red recombination84. Genomic truncations can occur as a result of double-strand breaks, however, which may mitigate the utility of Cas9 for implementing specific mutations85. For precision applications requiring single nucleotide resolution, nickases and base editors, which do not induce dsDNA breaks, are preferred.
Multiplexed genome editing has also been used to create animal models for studying combinatorial genotype-to-phenotype relationships and to engineer biallelic mutations of multiple genetic loci at once36,86. In the largest example of multiplexing to date, 62 gRNAs were transduced into pig cells in tandem to remove all copies of porcine endogenous retroviruses, with 8% of cells having 60–100% knockout rates87.
In metabolic engineering, more fine-tuned approaches to gene modulation are demanded, as the flux through a pathway must be tightly regulated to enhance production of a desired chemical without impinging upon growth (Fig. 4f). Multiplexed CRISPR–Cas technologies are frequently used to simultaneously activate and repress multiple genes at once, an approach that has been used to enhance cellobiose consumption in Yarrowia lipolytica, isoprenoid production in S. cerevisiae, and n-butanol and terpenoid production in E. coli88,89,90,91. More recently, a study increased succinic acid production approximately 150-fold in E. coli by co-expressing an inducible dCas9 with 20 sgRNAs to knockdown 6 genes48. Inducible dCas9 or gRNAs enable control over the timing and magnitude of metabolic pathway regulation, and can be used to implement growth decoupling mechanisms in vivo, whereby “growth” and “bioproduction” states are toggled at will to enhance fermentation yields once a population of cells reach a desired biomass92. Our group has also previously used xylose-inducible, multiplexed CRISPRi with three gRNAs (targeting N-Acetylglucosamine synthesis, glycolysis and peptidoglycan synthesis) to engineer a GlcNac overproducer Bacillus subtilis that can simultaneously co-utilize glucose and xylose, a feat not possible by many wild-type bacteria because of carbon catabolite repression93.
Insights and challenges of multiplexed crispr technologies
Despite the utility of multiplexed CRISPR technologies, serious biological and technical challenges remain. Perhaps most important, from an engineering standpoint, are the current difficulties in creating long arrays of gRNAs, and in predicting how these gRNAs will behave in living cells. The technical challenge of array assembly is rapidly being surmounted, thanks to better DNA synthesis chemistry and the development of orthogonal Cas9 handles that minimize repetitive sequences in sgRNA constructs, which were previously discussed48.
While we envision that current challenges in DNA synthesis and gRNA design, for example, will be overcome in the near future, other challenges will take longer to solve. One prominent problem with using CRISPR multiplexing to cut multiple genetic loci at once is the emergence of undesired chromosomal rearrangements. Fortunately, some studies have used paired sets of gRNAs to make specific cuts on chromosomes and then analyze the resulting rearrangements, and indicate that these large-scale rearrangements may be predictable in advance94.
Another serious challenge is that, as the number of gRNAs in a cell scales, they must compete for a dwindling ‘pool’ of endonucleases. This competition, in turn, alters the efficiency of every gRNA, an effect called retroactivity8. While synthetic biologists strive for modularity by combining many individually characterized genetic parts together, the interconnections between these parts often result in unpredictable outputs—this is especially pertinent for CRISPR–Cas multiplexing95. Retroactivity also makes it difficult to predict gRNA efficiency from sequence, another major obstacle for scaling multiplexed systems (Box 1).
Some studies have attempted to quantify the retroactive effects of multiplexed sgRNAs, and have demonstrated that titration of dCas9 with an increasing number of sgRNAs leads to predictable decreases in gRNA efficiencies96. In E. coli, sgRNAs for CRISPRi exhibited less than 10-fold repression once 7 or more sgRNAs were expressed (down from ~60-fold repression exhibited by the first sgRNA)8. A simple, ordinary differential equation model suggests that dCas9 bottlenecks cause CRISPRi target repression to drop off by roughly 1/N, where N is the number of sgRNAs expressed96. This effect was partly ameliorated in bacteria by using a dCas9-repressor fusion that recognizes a specific operator sequence and exhibits a lower toxicity, though this reduces the flexibility of DNA targeting8. dCas9 bottlenecking could possibly be mitigated by using conditional gRNAs, which are selectively triggered as needed in vivo62.
Cas9:gRNA complexes can recognize and bind genetic loci with as little as 5-nt of homology with the spacer, leading to off-target binding. Scaling the number of gRNAs within a cell enhances these off-target effects. Many sophisticated, genome-wide screens have assessed how parameters in gRNA spacer sequences, mismatches, and even the targeting of non-coding genes, can enhance off-target effects and deleteriously impact fitness for Cas9-mediated editing, CRISPRi and CRISPRa97,98,99. Fortunately, there are numerous strategies to mitigate off-target binding, including direct modification of the gRNA by shortening the spacer or truncation of one end of the tracrRNA element100,101. Other strategies employ mutant Cas9 endonucleases that function as nickases, with paired sets of gRNAs, which have been shown to reduce off-target effects as much as 1500-fold in certain cell lines compared to wild-type Cas9102. dCas9 can also be fused to FokI nuclease domains, which significantly improves target-specific editing compared to wild-type Cas9103,104. The recent development of search-and-replace genome editing, wherein nuclease-null Cas9 nickase is fused to an engineered reverse transcriptase, also enables DNA editing (insertions and all 12 types of base-to-base conversions) without double-strand breaks, and reduces off-target effects compared to wild-type Cas9105.
When working with gRNA-expressing arrays, one must account for context-dependent effects (Box 2). In some Csy4-processed arrays, for example, internally positioned gRNAs have lower expression compared to those placed on the ends of arrays34. gRNA arrays processed by Cas12a also vary drastically in mature RNA abundance based on their initial spatial position, likely due to the formation of stable, imperfect hairpins bridging spacer sequences23,24. In both cases, spatial effects can diminish gRNA expression and, in turn, efficiency.
Even in cases where numerous high-efficiency gRNAs are expressed, we still do not have a clear understanding of the limits for gRNA multiplexing in vivo. Despite our belief that hundreds of gRNAs could be expressed at once, it is unclear whether they would be effective due to increased competition for Cas enzymes. The processing efficiency of certain methods, including Csy4, ribozymes, and tRNA, will play a crucial role in determining the theoretical gRNA ceiling, and strategies to both create and process long arrays should be optimized in future studies.
CRISPR multiplexing offers a powerful approach to answer both fundamental and applied research questions. But despite the abundance of tools and techniques available, serious challenges remain. While some organisms encode 400 or more gRNAs within their CRISPR locus, engineered strategies have thus far been limited to arrays with just 25 gRNAs. However, it is feasible that existing methods of gRNA array assembly, as outlined in this review, will enable the in vivo expression of much longer arrays. Additionally, native CRISPR systems employ many Cas enzymes in tandem, each with specified functions, to transcribe, process, and utilize these gRNAs—we envision that the same could soon be accomplished with engineered organisms.
We suspect that future developments in the CRISPR multiplexing field will be limited not by a lack of CRISPR–Cas-based tools, but rather by deficiencies in our mechanistic understanding of how things like Cas toxicity, on- and off-target effects and orthogonality between CRISPR components actually operate in vivo106. Ongoing advancements in basic biology and genomics, computation, and chemistry will ameliorate some of the current bottlenecks in gRNA multiplexing. Chemistries for DNA synthesis have significantly improved in recent years, and some companies are now able to synthesize long, highly repetitive sequences, which will ease current technical challenges in producing arrays24. In addition, cleaner datasets of gene targeting efficiency and gRNA abundance produced from standardized next-generation sequencing protocols could enable highly predictive computational models for sgRNAs embedded within arrays, accounting for processing efficiency, spatial context of the genetic loci, and other factors (Box 2). In the future, a deeper, mechanistic understanding of gRNA:DNA binding may even enable highly precise modulation of gene expression, rather than the general up- and downregulation that is common today. Multiplexed gRNAs with “non-canonical” Cas enzymes, especially Cas13a, may enable all-in-one diagnostics for specific classes of viral and bacterial pathogens107. As the number of gRNAs that can be expressed in vivo expands, we also envision minimal cells that operate and respond to environmental cues via entirely synthetic, programmable, transcriptional regulatory networks67. The ability to rewire the metabolisms and genome regulatory networks of living cells could even help shift the planet away from a petroleum-based economy. CRISPR multiplexing will also serve as a crucial tool to probe deep questions in fundamental biology, particularly as our ability to precisely control transcription improves108.
The pace of research in CRISPR multiplexing has been astonishing. But to continue advancing in our ability to engineer living organisms, we will require rigorous, quantitative datasets that accurately capture the milieu of factors governing the efficiency of any engineered CRISPR–Cas technology. For example, scientists could study how parameters such as gRNA abundance impinge on gene expression using quantitative RNA-seq or quantify how specific gRNAs used with CRISPRi and CRISPRa alter the abundance of proteins using mass spectrometry (Box 2). With biologists, chemists and engineers working together, and quantitative measurements in hand, we may soon have the unprecedented ability to control, rewire, and program genomes in a totally predictable manner.
Marraffini, L. A. & Sontheimer, E. J. Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature 463, 568–571 (2010).
Mojica, F. J. M., Díez-Villaseñor, C., García-Martínez, J. & Almendros, C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733–740 (2009).
Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759–771 (2015).
Jinek, M. et al. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).
Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013). The first paper to show that dCas9 can be used to transcriptionally repress target genes.
Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451 (2013).
Bikard, D. et al. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 41, 7429–7437 (2013).
Zhang, S. & Voigt, C. A. Engineered dCas9 with reduced toxicity in bacteria: implications for genetic circuit design. Nucleic Acids Res. 46, 11115–11125 (2018).
Dong, C., Fontana, J., Patel, A., Carothers, J. M. & Zalatan, J. G. Synthetic CRISPR-Cas gene activators for transcriptional reprogramming in bacteria. Nat. Commun. 9, 1–11 (2018).
Chavez, A. et al. Comparison of Cas9 activators in multiple species. Nat. Methods 13, 563–567 (2016).
Chavez, A. et al. Highly efficient Cas9-mediated transcriptional programming. Nat. Methods 12, 326–328 (2015).
Tanenbaum, M. E., Gilbert, L. A., Qi, L. S., Weissman, J. S. & Vale, R. D. A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159, 635–646 (2014).
Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588 (2015).
Nielsen, A. A. & Voigt, C. A. Multi-input CRISPR/Cas genetic circuits that interface host regulatory networks. Mol. Syst. Biol. 10, 763–763 (2014).
Lian, J., Hamedirad, M., Hu, S. & Zhao, H. Combinatorial metabolic engineering using an orthogonal tri-functional CRISPR system. Nat. Commun. 8, 1688 (2017). This paper demonstrates that three 849 distinct CRISPR technologies – editing, activation, and repression – can function simultaneously in yeast cells by using 850 different Cas enzymes.
Gander, M. W., Vrana, J. D., Voje, W. E., Carothers, J. M. & Klavins, E. Digital logic circuits in yeast with CRISPR-dCas9 NOR gates. Nat. Commun. 8, 15459 (2017).
Jakočiūnas, T. et al. Multiplex metabolic pathway engineering using CRISPR/Cas9 in Saccharomyces cerevisiae. Metab. Eng. 28, 213–222 (2015).
Cheng, A. W. et al. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 23, 1163–1171 (2013).
Tak, Y. E. et al. Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors. Nat. Methods 14, 1163–1166 (2017). This paper demonstrates 873 multiplexed, inducible transcriptional activation in human cells using Cas12a.
McCarty, N. S., Shaw, W. M., Ellis, T. & Ledesma-Amaro, R. Rapid assembly of gRNA arrays via modular cloning in yeast. ACS Synth. Biol. 8, 906–910 (2019).
Charpentier, E., Richter, H., van der Oost, J. & White, M. F. Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity. FEMS Microbiol. Rev. 39, 428–441 (2015).
Alic, N. et al. Selectivity and proofreading both contribute significantly to the fidelity of RNA polymerase III transcription. Proc. Natl Acad. Sci. USA 104, 10400–10405 (2007).
Liao, C. et al. Modular one-pot assembly of CRISPR arrays enables library generation and reveals factors influencing crRNA biogenesis. Nat. Commun. 10, 2948 (2019). This 853 article presents a simple yet effective system for assembling gRNA arrays for Cas9, Cas12a, and Cas13a.
Campa, C. C., Weisbach, N. R., Santinha, A. J., Incarnato, D. & Platt, R. J. Multiplexed genome engineering by Cas12a and CRISPR arrays encoded on single transcripts. Nat. Methods 16, 887–893 (2019). This landmark paper 856 demonstrated that at least 25 individual crRNAs can be multiplexed from a single transcript with Cas12a.
Zetsche, B. et al. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array. Nat. Biotechnol. 35, 31–34 (2017).
Fonfara, I., Richter, H., BratoviÄ, M., Le Rhun, A. & Charpentier, E. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature 532, 517–521 (2016).
Wang, M., Mao, Y., Lu, Y., Tao, X. & Zhu, J. K. Multiplex gene editing in rice using the CRISPR-Cpf1 system. Mol. Plant 10, 1011–1013 (2017).
Swiat, M. A. et al. FnCpf1: a novel and efficient genome editing tool for Saccharomyces cerevisiae. Nucleic Acids Res. 45, 12585–12598 (2017).
Ao, X. et al. A multiplex genome editing method for Escherichia coli based on CRISPR-Cas12a. Front. Microbiol. 9, 1–13 (2018).
Nissim, L., Perli, S. D., Fridkin, A., Perez-Pinera, P. & Lu, T. K. Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. Mol. Cell 54, 698–710 (2014).
Deaner, M., Mejia, J. & Alper, H. S. Enabling graded and large-scale multiplex of desired genes using a dual-mode dCas9 activator in Saccharomyces cerevisiae. ACS Synth. Biol. 6, 1931–1943 (2017).
Xu, L., Zhao, L., Gao, Y., Xu, J. & Han, R. Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA. Nucleic Acids Res. 45, 1–9 (2017).
Haurwitz, R. E., Jinek, M., Wiedenheft, B., Zhou, K. & Doudna, J. A. Sequence- and structure-specific RNA processing by a CRISPR endonuclease. Science 329, 1205–1210 (2010).
Kurata, M., Wolf, N. K., Lahr, W. S., Weg, M. T. & Lee, S. Highly multiplexed genome engineering using CRISPR / Cas9 gRNA Arrays. PLoS ONE 13, e0198714 (2018).
Ferreira, R., Skrekas, C., Nielsen, J. & David, F. Multiplexed CRISPR/Cas9 genome editing and gene regulation using Csy4 in Saccharomyces cerevisiae. ACS Synth. Biol. 7, 10–15 (2018).
Xie, K., Minkenberg, B. & Yang, Y. Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system. Proc. Natl Acad. Sci. USA 112, 3570–3575 (2015).
Port, F. & Bullock, S. L. Augmenting CRISPR applications in Drosophila with tRNA-flanked sgRNAs. Nat. Methods 13, 852–854 (2016).
Zhang, Y. et al. A gRNA-tRNA array for CRISPR-Cas9 based rapid multiplexed genome editing in Saccharomyces cerevisiae. Nat. Commun. 10, 1–10 (2019).
Ding, D., Chen, K., Chen, Y., Li, H. & Xie, K. Engineering introns to express RNA guides for Cas9- and Cpf1-mediated multiplex genome editing. Mol. Plant 11, 542–552 (2018).
Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343–345 (2009).
Engler, C., Kandzia, R. & Marillonnet, S. A one pot, one step, precision cloning method with high throughput capability. PLoS ONE 3, e3647 (2008).
Xing, H. L. et al. A CRISPR/Cas9 toolkit for multiplex genome editing in plants. BMC Plant Biol. 14, 327 (2014).
Cress, B. F. et al. CRISPathBrick: modular combinatorial assembly of type II-A CRISPR arrays for dCas9-mediated multiplex transcriptional repression in E. coli. ACS Synth. Biol. 4, 987–1000 (2015).
Vad-Nielsen, J., Lin, L., Bolund, L., Nielsen, A. L. & Luo, Y. Golden gate assembly of CRISPR gRNA expression array for simultaneously targeting multiple genes. Cell. Mol. Life Sci. 73, 4315–4325 (2016).
Deaner, M., Holzman, A. & Alper, H. S. Modular ligation extension of guide RNA operons (LEGO) for multiplexed dCas9 regulation of metabolic pathways in Saccharomyces cerevisiae. Biotechnol. J. 13, e1700582 (2018).
Breunig, C. T. et al. One step generation of customizable gRNA vectors for multiplex CRISPR approaches through string assembly gRNA cloning (STAgR). PLoS ONE 13, e0196015 (2018).
Ledesma-Amaro, R., McCarty, N. S., Shaw, W. M. & Studena, L. CHORDs—Construction of Highly Ordered Repetitive DNA sequences. PCT/GB2019/052990 (2019).
Reis, A. C. et al. Simultaneous repression of multiple bacterial genes using nonrepetitive extra-long sgRNA arrays. Nat. Biotechnol. https://doi.org/10.1038/s41587-019-0286-9 (2019). This article presents extra859 long sgRNA arrays (ELSAs), a set of nonrepetitive DNA parts that enable the assembly and stable coexpression of arrays 860 with at least 22 gRNAs.
Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602–607 (2011).
Feng, X., Zhao, D., Zhang, X., Ding, X. & Bi, C. CRISPR / Cas9 assisted multiplex genome editing technique in Escherichia coli. Biotechnol. J. 13, e1700604 (2018).
Zhang, X. et al. Multiplex gene regulation by CRISPR-ddCpf1. Cell Discov. 3, 17018 (2017).
Brown, A. et al. Multiplexed and tunable transcriptional activation by promoter insertion using nuclease-assisted vector integration. Nucleic Acids Res. 47, e67 (2019).
Lowder, L. G. et al. Robust transcriptional activation in plants using multiplexed CRISPR-Act2.0 and mTALE-Act systems. Mol. Plant 11, 245–256 (2018).
Nowak, C. M., Lawson, S., Zerez, M. & Bleris, L. Guide RNA engineering for versatile Cas9 functionality. Nucleic Acids Res. 44, 9555–9564 (2016).
Briner, A. E. et al. Guide RNA functional modules direct Cas9 activity and orthogonality. Mol. Cell 56, 333–339 (2014).
Kweon, J. et al. Fusion guide RNAs for orthogonal gene manipulation with Cas9 and Cpf1. Nat. Commun. 8, 1723 (2017). A clever approach for multiplexing, this paper 866 demonstrates that fusion gRNAs can associate with both Cas9 and Cas12a to facilitate orthogonal genome manipulation.
Cho, S. et al. High-Level dCas9 expression induces abnormal cell morphology in Escherichia coli. ACS Synth. Biol. 7, 1085–1094 (2018).
Zalatan, J. G. et al. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160, 339–350 (2015).
Morse, N. J. et al. T7 polymerase expression of guide RNAs in vivo allows exportable CRISPR-Cas9 editing in multiple yeast hosts. ACS Synth. Biol. 7, 1075–1084 (2018).
Polstein, L. R. & Gersbach, C. A. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat. Chem. Biol. 11, 198–200 (2015).
Nakamura, M. et al. Anti-CRISPR-mediated control of gene editing and synthetic circuits in eukaryotic cells. Nat. Commun. 10, 1–11 (2019).
Hanewich-Hollatz, M. H., Chen, Z., Hochrein, L. M., Huang, J. & Pierce, N. A. Conditional guide RNAs: programmable conditional regulation of CRISPR/Cas function in bacterial and mammalian cells via dynamic RNA. Nanotechnol. ACS Cent. Sci. 5, 1241–1249 (2019).
Ferry, Q. R. V., Lyutova, R. & Fulga, T. A. Rational design of inducible CRISPR guide RNAs for de novo assembly of transcriptional programs. Nat. Commun. 8, 1–10 (2017). This paper presents a 863 clever method to inducibly control gRNA activity using both genetically-encoded and external triggers.
Wang, X. W. et al. A microRNA-inducible CRISPR–Cas9 platform serves as a microRNA sensor and cell-type-specific genome regulation tool. Nat. Cell Biol. 21, 522–530 (2019).
Rand, T. A., Petersen, S., Du, F. & Wang, X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123, 621–629 (2005).
Oesinghaus, L. & Simmel, F. C. Switching the activity of Cas12a using guide RNA strand displacement circuits. Nat. Commun. 10, 1–11 (2019).
Kim, H., Bojar, D. & Fussenegger, M. A CRISPR/Cas9-based central processing unit to program complex logic computation in human cells. Proc. Natl Acad. Sci. USA 116, 7214–7219 (2019).
Liu, Y. et al. Synthesizing and gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nat. Commun. 5, 1–7 (2014).
Li, Y., Li, S., Wang, J. & Liu, G. CRISPR/Cas systems towards next-generation biosensing. Trends Biotechnol. 37, 730–743 (2019).
East-Seletsky, A. et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature 538, 270–273 (2016).
Abudayyeh, O. O. et al. RNA targeting with CRISPR-Cas13. Nature 550, 280–284 (2017).
Li, S. Y. et al. CRISPR-Cas12a-assisted nucleic acid detection. Cell Discov. 4, 18–21 (2018).
Gootenberg, J. S. et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360, 439–444 (2018).
Li, S. Y. et al. CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA. Cell Res. 28, 491–493 (2018).
Zhang, Y. et al. Paired design of dCas9 as a systematic platform for the detection of featured nucleic Acid sequences in pathogenic strains. ACS Synth. Biol. 6, 211–216 (2017).
Wong, A. S. L. et al. Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM. Proc. Natl Acad. Sci. USA 113, 2544–2549 (2016).
Carleton, J. B., Berrett, K. C. & Gertz, J. Multiplex enhancer interference reveals collaborative control of gene regulation by estrogen receptor α-bound enhancers. Cell Syst. 5, 333–344.e5 (2017).
Gasperini, M. et al. A genome-wide framework for mapping gene regulation via cellular genetic screens. Cell 176, 377–390 (2019).
Adamson, B. et al. A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell 167, 1867–1882 (2016).
Sheth, R. U. & Wang, H. H. DNA-based memory devices for recording cellular events. Nat. Rev. Genet. 19, 718–732 (2018).
Tang, W. & Liu, D. R. Rewritable multi-event analog recording in bacterial and mammalian cells. Science 360, eaap8992 (2018).
Farzadfard, F. et al. Single-nucleotide-resolution computing and memory in living cells. Mol. Cell 75, 769–780 (2019).
Wang, K., Torre, D., De Robertson, W. E. & Chin, J. W. Programmed chromosome fission and fusion enable precise large-scale genome rearrangement and assembly. Science 926, 922–926 (2019).
Fredens, J. et al. Total synthesis of Escherichia coli with a recoded genome. Nature 569, 514–518 (2019).
Cullot, G. et al. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. Nat. Commun. 10, 1–14 (2019).
Li, W., Teng, F., Li, T. & Zhou, Q. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat. Biotechnol. 31, 684–686 (2013).
Yang, L. et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science 350, 1101–1104 (2015).
Schwartz, C., Curtis, N., Löbs, A.-K. & Wheeldon, I. Multiplexed CRISPR activation of cryptic sugar metabolism enables yarrowia lipolytica growth on cellobiose. Biotechnol. J. 1700584, 1–7 (2018).
Kim, S. K., Seong, W., Han, G. H., Lee, D. H. & Lee, S. G. CRISPR interference-guided multiplex repression of endogenous competing pathway genes for redirecting metabolic flux in Escherichia coli. Microb. Cell Fact. 16, 188 (2017).
Jensen, E. D. et al. Transcriptional reprogramming in yeast using dCas9 and combinatorial gRNA strategies. Microb. Cell Fact. 16, 1–16 (2017).
Kim, S. K. et al. CRISPR interference-guided balancing of a biosynthetic mevalonate pathway increases terpenoid production. Metab. Eng. 38, 228–240 (2016).
Li, S. et al. Enhanced protein and biochemical production using CRISPRi-based growth switches. Metab. Eng. 38, 274–284 (2016).
Wu, Y. et al. CRISPRi allows optimal temporal control of N-acetylglucosamine bioproduction by a dynamic coordination of glucose and xylose metabolism in Bacillus subtilis. Metab. Eng. 49, 232–241 (2018).
Shou, J., Li, J., Liu, Y. & Wu, Q. Precise and predictable CRISPR chromosomal rearrangements reveal principles of Cas9-mediated nucleotide insertion. Mol. Cell 71, 498–509.e4 (2018).
Qian, Y., Huang, H. H., Jiménez, J. I. & Del Vecchio, D. Resource competition shapes the response of genetic circuits. ACS Synth. Biol. 6, 1263–1272 (2017).
Chen, P. Y., Qian, Y. & Del Vecchio, D. A model for resource competition in CRISPR-mediated gene repression. Proc. IEEE Conf. Decis. Control. https://doi.org/10.1109/CDC.2018.8619016 (2018).
Tycko, J. et al. Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements. Nat. Commun. 10, 4063 (2019).
Morgens, D. W. et al. Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat. Commun. 8, 1–8 (2017).
Cui, L. et al. A CRISPRi screen in E. coli reveals sequence-specific toxicity of dCas9. Nat. Commun. 9, 1912 (2018).
Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31, 839–843 (2013).
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M. & Joung, J. K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279–284 (2014).
Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380–1389 (2013).
Guilinger, J. P., Thompson, D. B. & Liu, D. R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 32, 577–582 (2014).
Tsai, S. Q. et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat. Biotechnol. 32, 569–576 (2014).
Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature https://doi.org/10.1038/s41586-019-1711-4 (2019).
Jiang, F. & Doudna, J. A. CRISPR–Cas9 structures and mechanisms. Annu. Rev. Biophys. 46, 505–529 (2017).
Gootenberg, J. S. et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356, 438 (2017). 442.
Wang, J., Lu, A., Bei, J., Zhao, G. & Wang, J. CRISPR/ddCas12a-based programmable and accurate gene regulation. Cell Discov. 5, 10–13 (2019).
Mans, R. et al. CRISPR/Cas9: a molecular Swiss army knife for simultaneous introduction of multiple genetic modifications in Saccharomyces cerevisiae. FEMS Yeast Res. 15, 1–15 (2015).
Bao, Z. et al. Homology-integrated CRISPR-Cas (HI-CRISPR) system for one-step multigene disruption in Saccharomyces cerevisiae. ACS Synth. Biol. 4, 585–594 (2015).
Jakočiunas, T. et al. CasEMBLR: Cas9-facilitated multiloci genomic integration of in vivo assembled DNA parts in Saccharomyces cerevisiae. ACS Synth. Biol. 4, 1126–1134 (2015).
Walter, J. M., Chandran, S. S. & Horwitz, A. A. CRISPR-Cas-assisted multiplexing (CAM): simple same-day multi-locus engineering in yeast. J. Cell. Physiol. https://doi.org/10.1002/jcp.25375 (2016).
Ryan, O. W. et al. Selection of chromosomal DNA libraries using a multiplex CRISPR system. Elife https://doi.org/10.7554/eLife.03703 (2014).
Generoso, W. C., Gottardi, M., Oreb, M. & Boles, E. Simplified CRISPR-Cas genome editing for Saccharomyces cerevisiae. J. Microbiol. Methods 127, 203–205 (2016).
Zuckermann, M. et al. A novel cloning strategy for one-step assembly of multiplex CRISPR vectors. Sci. Rep. 8, 4–11 (2018).
Sakuma, T., Nishikawa, A., Kume, S., Chayama, K. & Yamamoto, T. Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. Sci. Rep. 4, 4–9 (2014).
Albers, J. et al. A versatile modular vector system for rapid combinatorial mammalian genetics. J. Clin. Invest. 125, 1603–1619 (2015).
Kabadi, A. M., Ousterout, D. G., Hilton, I. B. & Gersbach, C. A. Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res. https://doi.org/10.1093/nar/gku749 (2014).
Yin, L. et al. Multiplex conditional mutagenesis using transgenic expression of Cas9 and sgRNAs. Genetics https://doi.org/10.1534/genetics.115.176917 (2015).
Ma, X. et al. A robust CRISPR/Cas9 system for convenient, high-efficiency multiplex genome editing in monocot and dicot plants. Mol. Plant 8, 1274–1284 (2015).
Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32, 1262–1267 (2014).
Kim, D. et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat. Methods 12, 237–243 (2015).
Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187–198 (2015).
Crosetto, N. et al. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat. Methods 10, 361–365 (2013).
Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184–191 (2016).
Guo, J. et al. Improved sgRNA design in bacteria via genome-wide activity profiling. Nucleic Acids Res. 46, 7052–7069 (2018).
Smith, J. D. et al. Quantitative CRISPR interference screens in yeast identify chemical-genetic interactions and new rules for guide RNA design. Genome Biol. 17, 1–16 (2016).
Anderson, K. R. et al. CRISPR off-target analysis in genetically engineered rats and mice. Nat. Methods 15, 512–514 (2018).
Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832 (2013).
Labun, K. et al. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Res. 47, W171–W174 (2019).
Horlbeck, M. A. et al. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. Elife 5, 1–20 (2016).
Moreno-Mateos, M. A. et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat. Methods 12, 982–988 (2015).
Farasat, I. & Salis, H. M. A biophysical model of CRISPR/Cas9 activity for rational design of genome editing and gene regulation. PLoS Comput. Biol. 12, 1–33 (2016).
Torres-Perez, Garcia-Martin, Montoliu, Oliveros & Pazos WeReview: CRISPR tools—live repository of computational tools for assisting CRISPR/Cas experiments. Bioengineering 6, 63 (2019).
Haeussler, M. et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 17, 1–12 (2016).
Chuai, Ghui, Wang, Q. L. & Liu, Q. In silico meets in vivo: towards computational CRISPR-based sgRNA design. Trends Biotechnol. 35, 12–21 (2017).
Wang, D. et al. Optimized CRISPR guide RNA design for two high-fidelity Cas9 variants by deep learning. Nat. Commun. 10, 1–14 (2019).
Najm, F. J. et al. Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens. Nat. Biotechnol. 36, 179–189 (2018).
Kim, H. K. et al. Deep learning improves prediction of CRISPR-Cpf1 guide RNA activity. Nat. Biotechnol. 36, 239–241 (2018).
Gisler, S. et al. Multiplexed Cas9 targeting reveals genomic location effects and gRNA-based staggered breaks influencing mutation efficiency. Nat. Commun. 10, 1-14 (2019).
Labuhn, M. et al. Refined sgRNA efficacy prediction improves large and small-scale CRISPR-Cas9 applications. Nucleic Acids Res. 46, 1375–1385 (2018).
Vouillot, L., Thélie, A. & Pollet, N. Comparison of T7E1 and surveyor mismatch cleavage assays to detect mutations triggered by engineered nucleases. G3 5, 407–415 (2015).
R.L.A. received funding from Imperial College London in the form of an IC Research Fellowship and a BBSRC grant (BB/R01602X/1).
The authors declare no competing interests.
Peer review information Nature Communications thanks Chase Beisel and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
McCarty, N.S., Graham, A.E., Studená, L. et al. Multiplexed CRISPR technologies for gene editing and transcriptional regulation. Nat Commun 11, 1281 (2020). https://doi.org/10.1038/s41467-020-15053-x
Journal of Agricultural and Food Chemistry (2021)
Applied Microbiology and Biotechnology (2021)
CRISPR-Cas12a-Based Nucleic Acid Amplification-Free DNA Biosensor via Au Nanoparticle-Assisted Metal-Enhanced Fluorescence and Colorimetric Analysis
Nano Letters (2021)
CRISPR Gene-Editing Models Geared Toward Therapy for Hereditary and Developmental Neurological Disorders
Frontiers in Pediatrics (2021)
Journal of Molecular Cell Biology (2021)